Fig. 1

Prior treatment lines in patients with mCRC enrolled in the UK named patient programme. a Prior treatment lines for mCRC before trifluridine/tipiracil in patients receiving ≥1 dose; b Prior treatment lines for mCRC in patients who did not receive trifluridine/tipiracil. Percentages are not presented for groups with < 5% of patients. Treatments were grouped based on primary treatment. Treatment regimens were grouped as follows: (i) ‘FOLFIRI based’ includes FOLFIRI only or in combination with one or more of the following: aflibercept, bevacizumab, capecitabine, cetuximab, panitumumab. (ii) ‘FOLFOX based’ includes FOLFOX only or in combination with one or more of the following: bevacizumab, capecitabine, cetuximab, irinotecan, other. (iii) ‘CAPOX based’ includes CAPOX only or CAPOX with bevacizumab and/or other. (iv) ‘CAPIRI based’ includes CAPIRI only or CAPIRI with bevacizumab or cetuximab. (v) ‘Other capecitabine based’ includes capecitabine only or in combination with one or more of the following: aflibercept, bevacizumab, mitomycin, other. (vi) ‘Other 5-FU based’ includes 5-fluorouracil (5-FU) only or 5-FU plus capecitabine or other. (vii) ‘Other oxaliplatin based’ includes oxaliplatin only, oxaliplatin with irinotecan and cetuximab and oxaliplatin with other. (viii) ‘Other irinotecan based ‘ includes irinotecan only or in combination with one or more of the following: aflibercept, bevacizumab, cetuximab, other. (ix) ‘Cetuximab based’ includes cetuximab only or in combination with panitumumab. (x) ‘Regorafenib based’ includes regorafenib only or with other